Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0238


Preoperative chemoradiotherapy for rectal cancer: Why revision and concerns are now shaped?

Franco Roviello, MD

Affiliation: Professor Franco Roviello, Via A. De Gasperi, 5-53100 Siena, Italy

E-mail :

Since there is no abstract available we provide the first paragraph.
Over the past decade, neoadjuvant chemoradiotherapy has established as the standard approach for selected patients with advanced non-metastatic rectal cancer. But now meta-analyses, analysing data from more recent phase 3 randomized controlled trials raise a series of question and uncertainty about benefit-risk analysis neoadjuvant treatment. Given that this information is important not only for surgeons and oncologists but also patients, we describe benefits and complications of neoadjuvant treatment in a lack of robust biomarkers to predict who patients really respond and benefit from the preoperative chemoradiotherapy.

(Citation: Gastric & Breast Cancer 2012; 11(3): 154-156).



You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 July 2012